PREDICTIVE FACTORS FOR SUCCESSFUL BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS DOSE TAPERING IN RHEUMATOID ARTHRITIS

被引：0
|
作者：
Loh, Min Yi [1 ]
Jones, Claire J. [1 ]
Peall, Adrian [1 ]
Trickey, Jeanette [1 ]
机构：
[1] Wye Valley NHS Trust, Dept Rheumatol, Hereford, England
来源：
RHEUMATOLOGY | 2023年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E075
引用
收藏
页数：1
相关论文
共 50 条
  • [41] USE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS WITH OR WITHOUT METHOTREXATE FOR TREATMENT OF RHEUMATOID ARTHRITIS: A SINGLE CENTRE EXPERIENCE
    Leng, Pisaniello Huai
    Karen, O'Brien
    Malcolm, Smith
    Fiona, Goldblatt
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 29 - 29
  • [42] Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
    Convertino, Irma
    Cazzato, Massimiliano
    Tillati, Silvia
    Giometto, Sabrina
    Gini, Rosa
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Bonaso, Marco
    Bartolini, Claudia C.
    Paoletti, Olga
    Lorenzoni, Valentina
    Filippi, Matteo
    Turchetti, Giuseppe
    Cristofano, Michele
    Blandizzi, Corrado
    Mosca, Marta
    Lucenteforte, Ersilia
    Tuccori, Marco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 489
  • [43] Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study
    Tada, Masahiro
    Matsumoto, Yoshinari
    Koike, Tatsuya
    Mamoto, Kenji
    Nakamura, Tomoyuki
    Anno, Shohei
    Iida, Takahiro
    Goto, Hitoshi
    Hidaka, Noriaki
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (10)
  • [44] SECONDARY SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Abe, Asami
    Otani, Hiroshi
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1622 - 1622
  • [45] Pharmacogenetics of disease-modifying anti-rheumatic drugs
    Tanaka, E
    Taniguchi, A
    Urano, W
    Yamanaka, H
    Kamatani, N
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
  • [46] Factors predictive of treatment success of novel disease-modifying anti-rheumatic drugs (DMARDS) in patients with inflammatory arthritis
    Overbeek, Jetty A.
    Herings, Ron
    Moens, Hein J. Bernelot
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 229 - 229
  • [47] Disease-modifying anti-rheumatic drugs - Cyclosporin
    Chaudhuri, K
    Torley, H
    Madhok, R
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1016 - 1021
  • [48] Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
    Choy, Ernest H.
    RHEUMATOLOGY, 2019, 58 : 51 - 55
  • [49] Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi
    Kim, Seoyoung
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3476 - 3479
  • [50] Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis
    Navarro-Millan, Iris
    Goyal, Parag
    Safford, Monika M.
    RHEUMATOLOGY, 2019, 58 (06) : 933 - 934
12345